Brief: Bioxyne Reports Qtrly Revenue A$17.2 Mln
28/01/2026 01:38
Jan 28 (Reuters) - Bioxyne Ltd BXN.AX: REPORTS A$17.2 MILLION QUARTERLY REVENUE Further company coverage: BXN.AX ((Reuters.Briefs@thomsonreuters.com;))
Recent news on BLS Pharmaceuticals
See all newsBrief: BLS Pharmaceuticals Posts Q1 FY27 Revenue A$26.7M
Brief: BLS Pharmaceuticals Reports Record Q1 FY27 Revenue Of A$26.7 Million
Australia's BLS Pharmaceuticals extends gains on upbeat outlook, strong results
Brief: BLS Pharmaceuticals Sees FY27 Adjusted. EBITDA Margin 23% - 26%
Brief: BLS Pharmaceuticals Posts FY Net Profit After Tax Of A$15.4 MLN